One of the main causes of death in sepsis is acute lung damage (ALI) linked to the condition. As a result, numerous pharmacological and nonpharmacological techniques have been used to slow its progression. Few of these tactics have actually been successful. The epidemiology and pathophysiology of ALI, frequently used pharmacologic and nonpharmacologic treatments, and novel therapeutic modalities that are anticipated to be the subject of future trials are all covered in this article.
